Cargando…

Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas

In silico drug design using virtual screening, absorption, distribution, metabolism and excretion (ADME)/Tox data analysis, automated docking and molecular dynamics simulations for the determination of lead compounds for further in vitro analysis is a cost effective strategy. The present study used...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Guo-Fang, Huang, Zuo-An, Du, Xue-Kui, Yang, Ming-Lei, Huang, Dan-Dan, Zhang, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940108/
https://www.ncbi.nlm.nih.gov/pubmed/27279494
http://dx.doi.org/10.3892/mmr.2016.5350
_version_ 1782442105045516288
author Zhao, Guo-Fang
Huang, Zuo-An
Du, Xue-Kui
Yang, Ming-Lei
Huang, Dan-Dan
Zhang, Shun
author_facet Zhao, Guo-Fang
Huang, Zuo-An
Du, Xue-Kui
Yang, Ming-Lei
Huang, Dan-Dan
Zhang, Shun
author_sort Zhao, Guo-Fang
collection PubMed
description In silico drug design using virtual screening, absorption, distribution, metabolism and excretion (ADME)/Tox data analysis, automated docking and molecular dynamics simulations for the determination of lead compounds for further in vitro analysis is a cost effective strategy. The present study used this strategy to discover novel lead compounds from an in-house database of Traditional Chinese Medicinal (TCM) compounds against epithelial growth factor receptor (EGFR) protein for targeting non-small cell lung cancer (NSCLC). After virtual screening of an initial dataset of 2,242 TCM compounds, leads were identified based on binding energy and ADME/Tox data and subjected to automated docking followed by molecular dynamics simulation. Triptolide, a top compound identified by this vigorous in silico screening, was then tested in vitro on the H2347 cell line carrying wild-type EGFR, revealing an anti-proliferative potency similar to that of known drugs against NSCLC.
format Online
Article
Text
id pubmed-4940108
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-49401082016-07-21 Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas Zhao, Guo-Fang Huang, Zuo-An Du, Xue-Kui Yang, Ming-Lei Huang, Dan-Dan Zhang, Shun Mol Med Rep Articles In silico drug design using virtual screening, absorption, distribution, metabolism and excretion (ADME)/Tox data analysis, automated docking and molecular dynamics simulations for the determination of lead compounds for further in vitro analysis is a cost effective strategy. The present study used this strategy to discover novel lead compounds from an in-house database of Traditional Chinese Medicinal (TCM) compounds against epithelial growth factor receptor (EGFR) protein for targeting non-small cell lung cancer (NSCLC). After virtual screening of an initial dataset of 2,242 TCM compounds, leads were identified based on binding energy and ADME/Tox data and subjected to automated docking followed by molecular dynamics simulation. Triptolide, a top compound identified by this vigorous in silico screening, was then tested in vitro on the H2347 cell line carrying wild-type EGFR, revealing an anti-proliferative potency similar to that of known drugs against NSCLC. D.A. Spandidos 2016-08 2016-05-27 /pmc/articles/PMC4940108/ /pubmed/27279494 http://dx.doi.org/10.3892/mmr.2016.5350 Text en Copyright: © Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhao, Guo-Fang
Huang, Zuo-An
Du, Xue-Kui
Yang, Ming-Lei
Huang, Dan-Dan
Zhang, Shun
Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title_full Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title_fullStr Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title_full_unstemmed Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title_short Molecular docking studies of Traditional Chinese Medicinal compounds against known protein targets to treat non-small cell lung carcinomas
title_sort molecular docking studies of traditional chinese medicinal compounds against known protein targets to treat non-small cell lung carcinomas
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940108/
https://www.ncbi.nlm.nih.gov/pubmed/27279494
http://dx.doi.org/10.3892/mmr.2016.5350
work_keys_str_mv AT zhaoguofang moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas
AT huangzuoan moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas
AT duxuekui moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas
AT yangminglei moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas
AT huangdandan moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas
AT zhangshun moleculardockingstudiesoftraditionalchinesemedicinalcompoundsagainstknownproteintargetstotreatnonsmallcelllungcarcinomas